Dr Kerryn A Moore
Research Fellow - Malaria & Infectious Diseases Ep
Melbourne School of Population and Global Health
42 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
The Malaria Vaccine Implementation Programme study area in Ghana: results of a household survey prior to the introduction of the RTS,S/AS01 vaccine
DOI: 10.1186/s12936-025-05778-92026
Journal article
Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia
DOI: 10.1016/j.jinf.2026.1067272026
Journal article
Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial
DOI: 10.3389/fimmu.2026.17892482025
Journal article
Pneumococcal density and respiratory co-detection in severe pediatric pneumonia in Laos
DOI: 10.1038/s41598-025-01659-y2025
Journal article
Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial
DOI: 10.1016/j.vaccine.2025.1278402025
Journal article
The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose
DOI: 10.1016/j.jinf.2025.1064472024
Research grants (ARC, NHMRC, MRFF)
Epidemiological Evidence to Inform Policy on Optimal and Equitable Access to Pneumococcal Vaccination in the Asia-Pacific Region
RECENT SCHOLARLY WORKS
2025
Journal article
Immunogenicity of fractional and standard dose COVID-19 vaccine boosters among healthy adults in Indonesia: twenty four month follow-up from a randomised controlled trial
DOI: 10.1038/s41467-025-63598-62024
Journal article
Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi
DOI: 10.1016/S0140-6736(24)00004-72024
Journal article
Immunogenicity, safety, and reactogenicity of a halfversus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial
DOI: 10.1016/j.lanwpc.2023.1009532022
Journal article
Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings
DOI: 10.1080/14760584.2021.1965474